Immediate Impact
1 from Science/Nature 61 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Global incidence and mortality of severe fungal disease
2024 Standout
Works of Mitsuhiro Kamimura being referenced
Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
2023
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
2014
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Mitsuhiro Kamimura | 296 | 45 | 31 | 233 | 70 | 38 | 406 | |
| Akihiro Yoshimura | 206 | 58 | 24 | 252 | 116 | 43 | 446 | |
| Takeo Endo | 252 | 107 | 35 | 214 | 38 | 24 | 397 | |
| Giulia Sartori | 130 | 48 | 31 | 196 | 114 | 27 | 364 | |
| Juan Escrivá | 301 | 51 | 69 | 78 | 56 | 25 | 430 | |
| Toshiro Miwa | 117 | 67 | 36 | 154 | 62 | 43 | 349 | |
| Chengcai Liang | 146 | 22 | 93 | 98 | 82 | 32 | 359 | |
| Seisuke Okazawa | 132 | 92 | 35 | 161 | 63 | 43 | 444 | |
| Vincenzo Di Noia | 225 | 35 | 27 | 190 | 123 | 25 | 411 | |
| Qiang Su | 168 | 9 | 23 | 247 | 70 | 33 | 422 | |
| Tingting Liu | 206 | 20 | 28 | 63 | 38 | 44 | 356 |
All Works
Login with ORCID to disown or claim papers
Loading papers...